img

Global Drugs for Central Nervous System Market Insights, Forecast to 2034

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Drugs for Central Nervous System Market Insights, Forecast to 2034

The central nervous system (CNS) is the part of thenervous system consisting of the brain and spinal cord. In this report, we study the drugs for central nervous system disease.
Global Drugs for Central Nervous System market is expected to reach to US$ 121020 million in 2024, with a positive growth of %, compared with US$ 115260 million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Drugs for Central Nervous System industry is evaluated to reach US$ 186780 million in 2029. The CAGR will be 7.5% during 2024 to 2029.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Covers
This report presents an overview of global Drugs for Central Nervous System market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Drugs for Central Nervous System market with multiple angles. Items like regional sales, revenue from 2018 to 2029 and manufacturers’ sales, price, revenue and gross margin from 2018 to 2024 are analyzed. In addition, sales and revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Manufacturers, Type, Application and Regions Listed in the Report



By Company


Biogen
Pfizer
Teva
Novartis
Johnson & Johnson
EliLilly
Otsuka
Merck
AstraZeneca
Novartis
Takeda
Segment by Type
OTC
Rx Drugs

Segment by Application


Hospital
Retail Pharmacy

Segment by Region


US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
UK
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue and sales volume analysis from 2018 to 2029
Chapter 3Manufacturers’ sales, revenue and price analysis, including manufacturers’ Drugs for Central Nervous System plant distribution, commercial date of Drugs for Central Nervous System, product type offered, Mergers & Acquisitions and expansion activities.
Chapter 4Product sales, revenue and price analysis by type from 2018 to 2029 globally
Chapter 5Product sales, revenue and price analysis by application from 2018 to 2029 globally
Chapter 6Product sales, revenue analysis by type and application from 2018 to 2029 in US & Canada. Product sales and revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product sales, revenue analysis by type and application from 2018 to 2029 in Europe. Product sales and revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product sales, revenue analysis by type and application from 2018 to 2029 in China. Product sales and revenue analysis of China from 2018 to 2029
Chapter 9Product sales, revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product sales and revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product sales, revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product sales and revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Manufacturers’ outline, covering company’s basic information, major business, Drugs for Central Nervous System introduction, etc. Drugs for Central Nervous System Sales, Revenue, Price and Gross Margin of each company from 2018 to 2024
Chapter 12Industry chain analysis, like raw materials, manufacturing cost. Market channel, distributors and customers analysis
Chapter 13Market opportunities and challenges analysis
Chapter 14Mr Accuracy reports’s Conclusions of Drugs for Central Nervous System
Chapter 15Methodology and Data Sources adopted by Mr Accuracy reports

Table of Content

1 Study Coverage
1.1 Drugs for Central Nervous System Product Introduction
1.2 Market by Type
1.2.1 Global Drugs for Central Nervous System Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 OTC
1.2.3 Rx Drugs
1.3 Market by Application
1.3.1 Global Drugs for Central Nervous System Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Hospital
1.3.3 Retail Pharmacy
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Drugs for Central Nervous System Sales Estimates and Forecasts 2018-2029
2.2 Global Drugs for Central Nervous System Revenue by Region
2.2.1 Global Drugs for Central Nervous System Revenue by Region: 2018 VS 2022 VS 2029
2.2.2 Global Drugs for Central Nervous System Revenue by Region (2018-2024)
2.2.3 Global Drugs for Central Nervous System Revenue by Region (2024-2029)
2.2.4 Global Drugs for Central Nervous System Revenue Market Share by Region (2018-2029)
2.3 Global Drugs for Central Nervous System Sales Estimates and Forecasts 2018-2029
2.4 Global Drugs for Central Nervous System Sales by Region
2.4.1 Global Drugs for Central Nervous System Sales by Region: 2018 VS 2022 VS 2029
2.4.2 Global Drugs for Central Nervous System Sales by Region (2018-2024)
2.4.3 Global Drugs for Central Nervous System Sales by Region (2024-2029)
2.4.4 Global Drugs for Central Nervous System Sales Market Share by Region (2018-2029)
2.5 US & Canada
2.6 Europe
2.7 China
2.8 Asia (excluding China)
2.9 Middle East, Africa and Latin America
3 Competition by Manufactures
3.1 Global Drugs for Central Nervous System Sales by Manufacturers
3.1.1 Global Drugs for Central Nervous System Sales by Manufacturers (2018-2024)
3.1.2 Global Drugs for Central Nervous System Sales Market Share by Manufacturers (2018-2024)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Drugs for Central Nervous System in 2022
3.2 Global Drugs for Central Nervous System Revenue by Manufacturers
3.2.1 Global Drugs for Central Nervous System Revenue by Manufacturers (2018-2024)
3.2.2 Global Drugs for Central Nervous System Revenue Market Share by Manufacturers (2018-2024)
3.2.3 Global Top 10 and Top 5 Companies by Drugs for Central Nervous System Revenue in 2022
3.3 Global Key Players of Drugs for Central Nervous System, Industry Ranking, 2021 VS 2022 VS 2024
3.4 Global Drugs for Central Nervous System Sales Price by Manufacturers
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Drugs for Central Nervous System Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Drugs for Central Nervous System, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Drugs for Central Nervous System, Product Offered and Application
3.8 Global Key Manufacturers of Drugs for Central Nervous System, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Drugs for Central Nervous System Sales by Type
4.1.1 Global Drugs for Central Nervous System Historical Sales by Type (2018-2024)
4.1.2 Global Drugs for Central Nervous System Forecasted Sales by Type (2024-2029)
4.1.3 Global Drugs for Central Nervous System Sales Market Share by Type (2018-2029)
4.2 Global Drugs for Central Nervous System Revenue by Type
4.2.1 Global Drugs for Central Nervous System Historical Revenue by Type (2018-2024)
4.2.2 Global Drugs for Central Nervous System Forecasted Revenue by Type (2024-2029)
4.2.3 Global Drugs for Central Nervous System Revenue Market Share by Type (2018-2029)
4.3 Global Drugs for Central Nervous System Price by Type
4.3.1 Global Drugs for Central Nervous System Price by Type (2018-2024)
4.3.2 Global Drugs for Central Nervous System Price Forecast by Type (2024-2029)
5 Market Size by Application
5.1 Global Drugs for Central Nervous System Sales by Application
5.1.1 Global Drugs for Central Nervous System Historical Sales by Application (2018-2024)
5.1.2 Global Drugs for Central Nervous System Forecasted Sales by Application (2024-2029)
5.1.3 Global Drugs for Central Nervous System Sales Market Share by Application (2018-2029)
5.2 Global Drugs for Central Nervous System Revenue by Application
5.2.1 Global Drugs for Central Nervous System Historical Revenue by Application (2018-2024)
5.2.2 Global Drugs for Central Nervous System Forecasted Revenue by Application (2024-2029)
5.2.3 Global Drugs for Central Nervous System Revenue Market Share by Application (2018-2029)
5.3 Global Drugs for Central Nervous System Price by Application
5.3.1 Global Drugs for Central Nervous System Price by Application (2018-2024)
5.3.2 Global Drugs for Central Nervous System Price Forecast by Application (2024-2029)
6 US & Canada
6.1 US & Canada Drugs for Central Nervous System Market Size by Type
6.1.1 US & Canada Drugs for Central Nervous System Sales by Type (2018-2029)
6.1.2 US & Canada Drugs for Central Nervous System Revenue by Type (2018-2029)
6.2 US & Canada Drugs for Central Nervous System Market Size by Application
6.2.1 US & Canada Drugs for Central Nervous System Sales by Application (2018-2029)
6.2.2 US & Canada Drugs for Central Nervous System Revenue by Application (2018-2029)
6.3 US & Canada Drugs for Central Nervous System Market Size by Country
6.3.1 US & Canada Drugs for Central Nervous System Revenue by Country: 2018 VS 2022 VS 2029
6.3.2 US & Canada Drugs for Central Nervous System Sales by Country (2018-2029)
6.3.3 US & Canada Drugs for Central Nervous System Revenue by Country (2018-2029)
6.3.4 US
6.3.5 Canada
7 Europe
7.1 Europe Drugs for Central Nervous System Market Size by Type
7.1.1 Europe Drugs for Central Nervous System Sales by Type (2018-2029)
7.1.2 Europe Drugs for Central Nervous System Revenue by Type (2018-2029)
7.2 Europe Drugs for Central Nervous System Market Size by Application
7.2.1 Europe Drugs for Central Nervous System Sales by Application (2018-2029)
7.2.2 Europe Drugs for Central Nervous System Revenue by Application (2018-2029)
7.3 Europe Drugs for Central Nervous System Market Size by Country
7.3.1 Europe Drugs for Central Nervous System Revenue by Country: 2018 VS 2022 VS 2029
7.3.2 Europe Drugs for Central Nervous System Sales by Country (2018-2029)
7.3.3 Europe Drugs for Central Nervous System Revenue by Country (2018-2029)
7.3.4 Germany
7.3.5 France
7.3.6 UK
7.3.7 Italy
7.3.8 Russia
8 China
8.1 China Drugs for Central Nervous System Market Size
8.1.1 China Drugs for Central Nervous System Sales (2018-2029)
8.1.2 China Drugs for Central Nervous System Revenue (2018-2029)
8.2 China Drugs for Central Nervous System Market Size by Application
8.2.1 China Drugs for Central Nervous System Sales by Application (2018-2029)
8.2.2 China Drugs for Central Nervous System Revenue by Application (2018-2029)
9 Asia (excluding China)
9.1 Asia Drugs for Central Nervous System Market Size by Type
9.1.1 Asia Drugs for Central Nervous System Sales by Type (2018-2029)
9.1.2 Asia Drugs for Central Nervous System Revenue by Type (2018-2029)
9.2 Asia Drugs for Central Nervous System Market Size by Application
9.2.1 Asia Drugs for Central Nervous System Sales by Application (2018-2029)
9.2.2 Asia Drugs for Central Nervous System Revenue by Application (2018-2029)
9.3 Asia Drugs for Central Nervous System Sales by Region
9.3.1 Asia Drugs for Central Nervous System Revenue by Region: 2018 VS 2022 VS 2029
9.3.2 Asia Drugs for Central Nervous System Revenue by Region (2018-2029)
9.3.3 Asia Drugs for Central Nervous System Sales by Region (2018-2029)
9.3.4 Japan
9.3.5 South Korea
9.3.6 China Taiwan
9.3.7 Southeast Asia
9.3.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Drugs for Central Nervous System Market Size by Type
10.1.1 Middle East, Africa and Latin America Drugs for Central Nervous System Sales by Type (2018-2029)
10.1.2 Middle East, Africa and Latin America Drugs for Central Nervous System Revenue by Type (2018-2029)
10.2 Middle East, Africa and Latin America Drugs for Central Nervous System Market Size by Application
10.2.1 Middle East, Africa and Latin America Drugs for Central Nervous System Sales by Application (2018-2029)
10.2.2 Middle East, Africa and Latin America Drugs for Central Nervous System Revenue by Application (2018-2029)
10.3 Middle East, Africa and Latin America Drugs for Central Nervous System Sales by Country
10.3.1 Middle East, Africa and Latin America Drugs for Central Nervous System Revenue by Country: 2018 VS 2022 VS 2029
10.3.2 Middle East, Africa and Latin America Drugs for Central Nervous System Revenue by Country (2018-2029)
10.3.3 Middle East, Africa and Latin America Drugs for Central Nervous System Sales by Country (2018-2029)
10.3.4 Brazil
10.3.5 Mexico
10.3.6 Turkey
10.3.7 Israel
10.3.8 GCC Countries
11 Company Profiles
11.1 Biogen
11.1.1 Biogen Company Information
11.1.2 Biogen Overview
11.1.3 Biogen Drugs for Central Nervous System Sales, Price, Revenue and Gross Margin (2018-2024)
11.1.4 Biogen Drugs for Central Nervous System Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Biogen Recent Developments
11.2 Pfizer
11.2.1 Pfizer Company Information
11.2.2 Pfizer Overview
11.2.3 Pfizer Drugs for Central Nervous System Sales, Price, Revenue and Gross Margin (2018-2024)
11.2.4 Pfizer Drugs for Central Nervous System Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Pfizer Recent Developments
11.3 Teva
11.3.1 Teva Company Information
11.3.2 Teva Overview
11.3.3 Teva Drugs for Central Nervous System Sales, Price, Revenue and Gross Margin (2018-2024)
11.3.4 Teva Drugs for Central Nervous System Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Teva Recent Developments
11.4 Novartis
11.4.1 Novartis Company Information
11.4.2 Novartis Overview
11.4.3 Novartis Drugs for Central Nervous System Sales, Price, Revenue and Gross Margin (2018-2024)
11.4.4 Novartis Drugs for Central Nervous System Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Novartis Recent Developments
11.5 Johnson & Johnson
11.5.1 Johnson & Johnson Company Information
11.5.2 Johnson & Johnson Overview
11.5.3 Johnson & Johnson Drugs for Central Nervous System Sales, Price, Revenue and Gross Margin (2018-2024)
11.5.4 Johnson & Johnson Drugs for Central Nervous System Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Johnson & Johnson Recent Developments
11.6 EliLilly
11.6.1 EliLilly Company Information
11.6.2 EliLilly Overview
11.6.3 EliLilly Drugs for Central Nervous System Sales, Price, Revenue and Gross Margin (2018-2024)
11.6.4 EliLilly Drugs for Central Nervous System Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 EliLilly Recent Developments
11.7 Otsuka
11.7.1 Otsuka Company Information
11.7.2 Otsuka Overview
11.7.3 Otsuka Drugs for Central Nervous System Sales, Price, Revenue and Gross Margin (2018-2024)
11.7.4 Otsuka Drugs for Central Nervous System Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Otsuka Recent Developments
11.8 Merck
11.8.1 Merck Company Information
11.8.2 Merck Overview
11.8.3 Merck Drugs for Central Nervous System Sales, Price, Revenue and Gross Margin (2018-2024)
11.8.4 Merck Drugs for Central Nervous System Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Merck Recent Developments
11.9 AstraZeneca
11.9.1 AstraZeneca Company Information
11.9.2 AstraZeneca Overview
11.9.3 AstraZeneca Drugs for Central Nervous System Sales, Price, Revenue and Gross Margin (2018-2024)
11.9.4 AstraZeneca Drugs for Central Nervous System Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 AstraZeneca Recent Developments
11.10 Novartis
11.10.1 Novartis Company Information
11.10.2 Novartis Overview
11.10.3 Novartis Drugs for Central Nervous System Sales, Price, Revenue and Gross Margin (2018-2024)
11.10.4 Novartis Drugs for Central Nervous System Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Novartis Recent Developments
11.11 Takeda
11.11.1 Takeda Company Information
11.11.2 Takeda Overview
11.11.3 Takeda Drugs for Central Nervous System Sales, Price, Revenue and Gross Margin (2018-2024)
11.11.4 Takeda Drugs for Central Nervous System Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 Takeda Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Drugs for Central Nervous System Industry Chain Analysis
12.2 Drugs for Central Nervous System Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Drugs for Central Nervous System Production Mode & Process
12.4 Drugs for Central Nervous System Sales and Marketing
12.4.1 Drugs for Central Nervous System Sales Channels
12.4.2 Drugs for Central Nervous System Distributors
12.5 Drugs for Central Nervous System Customers
13 Market Dynamics
13.1 Drugs for Central Nervous System Industry Trends
13.2 Drugs for Central Nervous System Market Drivers
13.3 Drugs for Central Nervous System Market Challenges
13.4 Drugs for Central Nervous System Market Restraints
14 Key Findings in The Global Drugs for Central Nervous System Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Drugs for Central Nervous System Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Table 2. Major Manufacturers of OTC
Table 3. Major Manufacturers of Rx Drugs
Table 4. Global Drugs for Central Nervous System Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Table 5. Global Drugs for Central Nervous System Revenue Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 6. Global Drugs for Central Nervous System Revenue by Region (2018-2024) & (US$ Million)
Table 7. Global Drugs for Central Nervous System Revenue by Region (2024-2029) & (US$ Million)
Table 8. Global Drugs for Central Nervous System Revenue Market Share by Region (2018-2024)
Table 9. Global Drugs for Central Nervous System Revenue Market Share by Region (2024-2029)
Table 10. Global Drugs for Central Nervous System Sales Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 11. Global Drugs for Central Nervous System Sales by Region (2018-2024) & (K Units)
Table 12. Global Drugs for Central Nervous System Sales by Region (2024-2029) & (K Units)
Table 13. Global Drugs for Central Nervous System Sales Market Share by Region (2018-2024)
Table 14. Global Drugs for Central Nervous System Sales Market Share by Region (2024-2029)
Table 15. Global Drugs for Central Nervous System Sales by Manufacturers (2018-2024) & (K Units)
Table 16. Global Drugs for Central Nervous System Sales Share by Manufacturers (2018-2024)
Table 17. Global Drugs for Central Nervous System Revenue by Manufacturers (2018-2024) & (US$ Million)
Table 18. Global Drugs for Central Nervous System Revenue Share by Manufacturers (2018-2024)
Table 19. Global Key Players of Drugs for Central Nervous System, Industry Ranking, 2021 VS 2022 VS 2024
Table 20. Drugs for Central Nervous System Price by Manufacturers 2018-2024 (USD/Unit)
Table 21. Global Drugs for Central Nervous System Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 22. Global Drugs for Central Nervous System by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Drugs for Central Nervous System as of 2022)
Table 23. Global Key Manufacturers of Drugs for Central Nervous System, Manufacturing Base Distribution and Headquarters
Table 24. Global Key Manufacturers of Drugs for Central Nervous System, Product Offered and Application
Table 25. Global Key Manufacturers of Drugs for Central Nervous System, Date of Enter into This Industry
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Drugs for Central Nervous System Sales by Type (2018-2024) & (K Units)
Table 28. Global Drugs for Central Nervous System Sales by Type (2024-2029) & (K Units)
Table 29. Global Drugs for Central Nervous System Sales Share by Type (2018-2024)
Table 30. Global Drugs for Central Nervous System Sales Share by Type (2024-2029)
Table 31. Global Drugs for Central Nervous System Revenue by Type (2018-2024) & (US$ Million)
Table 32. Global Drugs for Central Nervous System Revenue by Type (2024-2029) & (US$ Million)
Table 33. Global Drugs for Central Nervous System Revenue Share by Type (2018-2024)
Table 34. Global Drugs for Central Nervous System Revenue Share by Type (2024-2029)
Table 35. Drugs for Central Nervous System Price by Type (2018-2024) & (USD/Unit)
Table 36. Global Drugs for Central Nervous System Price Forecast by Type (2024-2029) & (USD/Unit)
Table 37. Global Drugs for Central Nervous System Sales by Application (2018-2024) & (K Units)
Table 38. Global Drugs for Central Nervous System Sales by Application (2024-2029) & (K Units)
Table 39. Global Drugs for Central Nervous System Sales Share by Application (2018-2024)
Table 40. Global Drugs for Central Nervous System Sales Share by Application (2024-2029)
Table 41. Global Drugs for Central Nervous System Revenue by Application (2018-2024) & (US$ Million)
Table 42. Global Drugs for Central Nervous System Revenue by Application (2024-2029) & (US$ Million)
Table 43. Global Drugs for Central Nervous System Revenue Share by Application (2018-2024)
Table 44. Global Drugs for Central Nervous System Revenue Share by Application (2024-2029)
Table 45. Drugs for Central Nervous System Price by Application (2018-2024) & (USD/Unit)
Table 46. Global Drugs for Central Nervous System Price Forecast by Application (2024-2029) & (USD/Unit)
Table 47. US & Canada Drugs for Central Nervous System Sales by Type (2018-2024) & (K Units)
Table 48. US & Canada Drugs for Central Nervous System Sales by Type (2024-2029) & (K Units)
Table 49. US & Canada Drugs for Central Nervous System Revenue by Type (2018-2024) & (US$ Million)
Table 50. US & Canada Drugs for Central Nervous System Revenue by Type (2024-2029) & (US$ Million)
Table 51. US & Canada Drugs for Central Nervous System Sales by Application (2018-2024) & (K Units)
Table 52. US & Canada Drugs for Central Nervous System Sales by Application (2024-2029) & (K Units)
Table 53. US & Canada Drugs for Central Nervous System Revenue by Application (2018-2024) & (US$ Million)
Table 54. US & Canada Drugs for Central Nervous System Revenue by Application (2024-2029) & (US$ Million)
Table 55. US & Canada Drugs for Central Nervous System Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 56. US & Canada Drugs for Central Nervous System Revenue by Country (2018-2024) & (US$ Million)
Table 57. US & Canada Drugs for Central Nervous System Revenue by Country (2024-2029) & (US$ Million)
Table 58. US & Canada Drugs for Central Nervous System Sales by Country (2018-2024) & (K Units)
Table 59. US & Canada Drugs for Central Nervous System Sales by Country (2024-2029) & (K Units)
Table 60. Europe Drugs for Central Nervous System Sales by Type (2018-2024) & (K Units)
Table 61. Europe Drugs for Central Nervous System Sales by Type (2024-2029) & (K Units)
Table 62. Europe Drugs for Central Nervous System Revenue by Type (2018-2024) & (US$ Million)
Table 63. Europe Drugs for Central Nervous System Revenue by Type (2024-2029) & (US$ Million)
Table 64. Europe Drugs for Central Nervous System Sales by Application (2018-2024) & (K Units)
Table 65. Europe Drugs for Central Nervous System Sales by Application (2024-2029) & (K Units)
Table 66. Europe Drugs for Central Nervous System Revenue by Application (2018-2024) & (US$ Million)
Table 67. Europe Drugs for Central Nervous System Revenue by Application (2024-2029) & (US$ Million)
Table 68. Europe Drugs for Central Nervous System Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 69. Europe Drugs for Central Nervous System Revenue by Country (2018-2024) & (US$ Million)
Table 70. Europe Drugs for Central Nervous System Revenue by Country (2024-2029) & (US$ Million)
Table 71. Europe Drugs for Central Nervous System Sales by Country (2018-2024) & (K Units)
Table 72. Europe Drugs for Central Nervous System Sales by Country (2024-2029) & (K Units)
Table 73. China Drugs for Central Nervous System Sales by Type (2018-2024) & (K Units)
Table 74. China Drugs for Central Nervous System Sales by Type (2024-2029) & (K Units)
Table 75. China Drugs for Central Nervous System Revenue by Type (2018-2024) & (US$ Million)
Table 76. China Drugs for Central Nervous System Revenue by Type (2024-2029) & (US$ Million)
Table 77. China Drugs for Central Nervous System Sales by Application (2018-2024) & (K Units)
Table 78. China Drugs for Central Nervous System Sales by Application (2024-2029) & (K Units)
Table 79. China Drugs for Central Nervous System Revenue by Application (2018-2024) & (US$ Million)
Table 80. China Drugs for Central Nervous System Revenue by Application (2024-2029) & (US$ Million)
Table 81. Asia Drugs for Central Nervous System Sales by Type (2018-2024) & (K Units)
Table 82. Asia Drugs for Central Nervous System Sales by Type (2024-2029) & (K Units)
Table 83. Asia Drugs for Central Nervous System Revenue by Type (2018-2024) & (US$ Million)
Table 84. Asia Drugs for Central Nervous System Revenue by Type (2024-2029) & (US$ Million)
Table 85. Asia Drugs for Central Nervous System Sales by Application (2018-2024) & (K Units)
Table 86. Asia Drugs for Central Nervous System Sales by Application (2024-2029) & (K Units)
Table 87. Asia Drugs for Central Nervous System Revenue by Application (2018-2024) & (US$ Million)
Table 88. Asia Drugs for Central Nervous System Revenue by Application (2024-2029) & (US$ Million)
Table 89. Asia Drugs for Central Nervous System Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 90. Asia Drugs for Central Nervous System Revenue by Region (2018-2024) & (US$ Million)
Table 91. Asia Drugs for Central Nervous System Revenue by Region (2024-2029) & (US$ Million)
Table 92. Asia Drugs for Central Nervous System Sales by Region (2018-2024) & (K Units)
Table 93. Asia Drugs for Central Nervous System Sales by Region (2024-2029) & (K Units)
Table 94. Middle East, Africa and Latin America Drugs for Central Nervous System Sales by Type (2018-2024) & (K Units)
Table 95. Middle East, Africa and Latin America Drugs for Central Nervous System Sales by Type (2024-2029) & (K Units)
Table 96. Middle East, Africa and Latin America Drugs for Central Nervous System Revenue by Type (2018-2024) & (US$ Million)
Table 97. Middle East, Africa and Latin America Drugs for Central Nervous System Revenue by Type (2024-2029) & (US$ Million)
Table 98. Middle East, Africa and Latin America Drugs for Central Nervous System Sales by Application (2018-2024) & (K Units)
Table 99. Middle East, Africa and Latin America Drugs for Central Nervous System Sales by Application (2024-2029) & (K Units)
Table 100. Middle East, Africa and Latin America Drugs for Central Nervous System Revenue by Application (2018-2024) & (US$ Million)
Table 101. Middle East, Africa and Latin America Drugs for Central Nervous System Revenue by Application (2024-2029) & (US$ Million)
Table 102. Middle East, Africa and Latin America Drugs for Central Nervous System Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 103. Middle East, Africa and Latin America Drugs for Central Nervous System Revenue by Country (2018-2024) & (US$ Million)
Table 104. Middle East, Africa and Latin America Drugs for Central Nervous System Revenue by Country (2024-2029) & (US$ Million)
Table 105. Middle East, Africa and Latin America Drugs for Central Nervous System Sales by Country (2018-2024) & (K Units)
Table 106. Middle East, Africa and Latin America Drugs for Central Nervous System Sales by Country (2024-2029) & (K Units)
Table 107. Biogen Company Information
Table 108. Biogen Description and Major Businesses
Table 109. Biogen Drugs for Central Nervous System Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 110. Biogen Drugs for Central Nervous System Product Model Numbers, Pictures, Descriptions and Specifications
Table 111. Biogen Recent Developments
Table 112. Pfizer Company Information
Table 113. Pfizer Description and Major Businesses
Table 114. Pfizer Drugs for Central Nervous System Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 115. Pfizer Drugs for Central Nervous System Product Model Numbers, Pictures, Descriptions and Specifications
Table 116. Pfizer Recent Developments
Table 117. Teva Company Information
Table 118. Teva Description and Major Businesses
Table 119. Teva Drugs for Central Nervous System Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 120. Teva Drugs for Central Nervous System Product Model Numbers, Pictures, Descriptions and Specifications
Table 121. Teva Recent Developments
Table 122. Novartis Company Information
Table 123. Novartis Description and Major Businesses
Table 124. Novartis Drugs for Central Nervous System Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 125. Novartis Drugs for Central Nervous System Product Model Numbers, Pictures, Descriptions and Specifications
Table 126. Novartis Recent Developments
Table 127. Johnson & Johnson Company Information
Table 128. Johnson & Johnson Description and Major Businesses
Table 129. Johnson & Johnson Drugs for Central Nervous System Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 130. Johnson & Johnson Drugs for Central Nervous System Product Model Numbers, Pictures, Descriptions and Specifications
Table 131. Johnson & Johnson Recent Developments
Table 132. EliLilly Company Information
Table 133. EliLilly Description and Major Businesses
Table 134. EliLilly Drugs for Central Nervous System Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 135. EliLilly Drugs for Central Nervous System Product Model Numbers, Pictures, Descriptions and Specifications
Table 136. EliLilly Recent Developments
Table 137. Otsuka Company Information
Table 138. Otsuka Description and Major Businesses
Table 139. Otsuka Drugs for Central Nervous System Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 140. Otsuka Drugs for Central Nervous System Product Model Numbers, Pictures, Descriptions and Specifications
Table 141. Otsuka Recent Developments
Table 142. Merck Company Information
Table 143. Merck Description and Major Businesses
Table 144. Merck Drugs for Central Nervous System Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 145. Merck Drugs for Central Nervous System Product Model Numbers, Pictures, Descriptions and Specifications
Table 146. Merck Recent Developments
Table 147. AstraZeneca Company Information
Table 148. AstraZeneca Description and Major Businesses
Table 149. AstraZeneca Drugs for Central Nervous System Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 150. AstraZeneca Drugs for Central Nervous System Product Model Numbers, Pictures, Descriptions and Specifications
Table 151. AstraZeneca Recent Developments
Table 152. Novartis Company Information
Table 153. Novartis Description and Major Businesses
Table 154. Novartis Drugs for Central Nervous System Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 155. Novartis Drugs for Central Nervous System Product Model Numbers, Pictures, Descriptions and Specifications
Table 156. Novartis Recent Developments
Table 157. Takeda Company Information
Table 158. Takeda Description and Major Businesses
Table 159. Takeda Drugs for Central Nervous System Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 160. Takeda Drugs for Central Nervous System Product Model Numbers, Pictures, Descriptions and Specifications
Table 161. Takeda Recent Developments
Table 162. Key Raw Materials Lists
Table 163. Raw Materials Key Suppliers Lists
Table 164. Drugs for Central Nervous System Distributors List
Table 165. Drugs for Central Nervous System Customers List
Table 166. Drugs for Central Nervous System Market Trends
Table 167. Drugs for Central Nervous System Market Drivers
Table 168. Drugs for Central Nervous System Market Challenges
Table 169. Drugs for Central Nervous System Market Restraints
Table 170. Research Programs/Design for This Report
Table 171. Key Data Information from Secondary Sources
Table 172. Key Data Information from Primary Sources
List of Figures
Figure 1. Drugs for Central Nervous System Product Picture
Figure 2. Global Drugs for Central Nervous System Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Figure 3. Global Drugs for Central Nervous System Market Share by Type in 2022 & 2029
Figure 4. OTC Product Picture
Figure 5. Rx Drugs Product Picture
Figure 6. Global Drugs for Central Nervous System Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Figure 7. Global Drugs for Central Nervous System Market Share by Application in 2022 & 2029
Figure 8. Hospital
Figure 9. Retail Pharmacy
Figure 10. Drugs for Central Nervous System Report Years Considered
Figure 11. Global Drugs for Central Nervous System Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 12. Global Drugs for Central Nervous System Revenue 2018-2029 (US$ Million)
Figure 13. Global Drugs for Central Nervous System Revenue Market Share by Region in Percentage: 2022 Versus 2029
Figure 14. Global Drugs for Central Nervous System Revenue Market Share by Region (2018-2029)
Figure 15. Global Drugs for Central Nervous System Sales 2018-2029 ((K Units)
Figure 16. Global Drugs for Central Nervous System Sales Market Share by Region (2018-2029)
Figure 17. US & Canada Drugs for Central Nervous System Sales YoY (2018-2029) & (K Units)
Figure 18. US & Canada Drugs for Central Nervous System Revenue YoY (2018-2029) & (US$ Million)
Figure 19. Europe Drugs for Central Nervous System Sales YoY (2018-2029) & (K Units)
Figure 20. Europe Drugs for Central Nervous System Revenue YoY (2018-2029) & (US$ Million)
Figure 21. China Drugs for Central Nervous System Sales YoY (2018-2029) & (K Units)
Figure 22. China Drugs for Central Nervous System Revenue YoY (2018-2029) & (US$ Million)
Figure 23. Asia (excluding China) Drugs for Central Nervous System Sales YoY (2018-2029) & (K Units)
Figure 24. Asia (excluding China) Drugs for Central Nervous System Revenue YoY (2018-2029) & (US$ Million)
Figure 25. Middle East, Africa and Latin America Drugs for Central Nervous System Sales YoY (2018-2029) & (K Units)
Figure 26. Middle East, Africa and Latin America Drugs for Central Nervous System Revenue YoY (2018-2029) & (US$ Million)
Figure 27. The Drugs for Central Nervous System Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2022
Figure 28. The Top 5 and 10 Largest Manufacturers of Drugs for Central Nervous System in the World: Market Share by Drugs for Central Nervous System Revenue in 2022
Figure 29. Global Drugs for Central Nervous System Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 30. Global Drugs for Central Nervous System Sales Market Share by Type (2018-2029)
Figure 31. Global Drugs for Central Nervous System Revenue Market Share by Type (2018-2029)
Figure 32. Global Drugs for Central Nervous System Sales Market Share by Application (2018-2029)
Figure 33. Global Drugs for Central Nervous System Revenue Market Share by Application (2018-2029)
Figure 34. US & Canada Drugs for Central Nervous System Sales Market Share by Type (2018-2029)
Figure 35. US & Canada Drugs for Central Nervous System Revenue Market Share by Type (2018-2029)
Figure 36. US & Canada Drugs for Central Nervous System Sales Market Share by Application (2018-2029)
Figure 37. US & Canada Drugs for Central Nervous System Revenue Market Share by Application (2018-2029)
Figure 38. US & Canada Drugs for Central Nervous System Revenue Share by Country (2018-2029)
Figure 39. US & Canada Drugs for Central Nervous System Sales Share by Country (2018-2029)
Figure 40. U.S. Drugs for Central Nervous System Revenue (2018-2029) & (US$ Million)
Figure 41. Canada Drugs for Central Nervous System Revenue (2018-2029) & (US$ Million)
Figure 42. Europe Drugs for Central Nervous System Sales Market Share by Type (2018-2029)
Figure 43. Europe Drugs for Central Nervous System Revenue Market Share by Type (2018-2029)
Figure 44. Europe Drugs for Central Nervous System Sales Market Share by Application (2018-2029)
Figure 45. Europe Drugs for Central Nervous System Revenue Market Share by Application (2018-2029)
Figure 46. Europe Drugs for Central Nervous System Revenue Share by Country (2018-2029)
Figure 47. Europe Drugs for Central Nervous System Sales Share by Country (2018-2029)
Figure 48. Germany Drugs for Central Nervous System Revenue (2018-2029) & (US$ Million)
Figure 49. France Drugs for Central Nervous System Revenue (2018-2029) & (US$ Million)
Figure 50. UK Drugs for Central Nervous System Revenue (2018-2029) & (US$ Million)
Figure 51. Italy Drugs for Central Nervous System Revenue (2018-2029) & (US$ Million)
Figure 52. Russia Drugs for Central Nervous System Revenue (2018-2029) & (US$ Million)
Figure 53. China Drugs for Central Nervous System Sales Market Share by Type (2018-2029)
Figure 54. China Drugs for Central Nervous System Revenue Market Share by Type (2018-2029)
Figure 55. China Drugs for Central Nervous System Sales Market Share by Application (2018-2029)
Figure 56. China Drugs for Central Nervous System Revenue Market Share by Application (2018-2029)
Figure 57. Asia Drugs for Central Nervous System Sales Market Share by Type (2018-2029)
Figure 58. Asia Drugs for Central Nervous System Revenue Market Share by Type (2018-2029)
Figure 59. Asia Drugs for Central Nervous System Sales Market Share by Application (2018-2029)
Figure 60. Asia Drugs for Central Nervous System Revenue Market Share by Application (2018-2029)
Figure 61. Asia Drugs for Central Nervous System Revenue Share by Region (2018-2029)
Figure 62. Asia Drugs for Central Nervous System Sales Share by Region (2018-2029)
Figure 63. Japan Drugs for Central Nervous System Revenue (2018-2029) & (US$ Million)
Figure 64. South Korea Drugs for Central Nervous System Revenue (2018-2029) & (US$ Million)
Figure 65. China Taiwan Drugs for Central Nervous System Revenue (2018-2029) & (US$ Million)
Figure 66. Southeast Asia Drugs for Central Nervous System Revenue (2018-2029) & (US$ Million)
Figure 67. India Drugs for Central Nervous System Revenue (2018-2029) & (US$ Million)
Figure 68. Middle East, Africa and Latin America Drugs for Central Nervous System Sales Market Share by Type (2018-2029)
Figure 69. Middle East, Africa and Latin America Drugs for Central Nervous System Revenue Market Share by Type (2018-2029)
Figure 70. Middle East, Africa and Latin America Drugs for Central Nervous System Sales Market Share by Application (2018-2029)
Figure 71. Middle East, Africa and Latin America Drugs for Central Nervous System Revenue Market Share by Application (2018-2029)
Figure 72. Middle East, Africa and Latin America Drugs for Central Nervous System Revenue Share by Country (2018-2029)
Figure 73. Middle East, Africa and Latin America Drugs for Central Nervous System Sales Share by Country (2018-2029)
Figure 74. Brazil Drugs for Central Nervous System Revenue (2018-2029) & (US$ Million)
Figure 75. Mexico Drugs for Central Nervous System Revenue (2018-2029) & (US$ Million)
Figure 76. Turkey Drugs for Central Nervous System Revenue (2018-2029) & (US$ Million)
Figure 77. Israel Drugs for Central Nervous System Revenue (2018-2029) & (US$ Million)
Figure 78. GCC Countries Drugs for Central Nervous System Revenue (2018-2029) & (US$ Million)
Figure 79. Drugs for Central Nervous System Value Chain
Figure 80. Drugs for Central Nervous System Production Process
Figure 81. Channels of Distribution
Figure 82. Distributors Profiles
Figure 83. Bottom-up and Top-down Approaches for This Report
Figure 84. Data Triangulation
Figure 85. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries